A diabetes drug is the subject of an FDA investigation, after the drug was found to cause unexpected side effects in diabetes patients who were taking the drug.
The diabetes drug in question is called dapagliflozin. Dapagliflozin was developed by Bristol-Myers Squibb Co. and AstraZeneca Plc. and is used to lower blood sugar levels. Persons with diabetes have high blood glucose levels.
If the blood glucose level in a diabetic patient remains high for a long period of time, there blood vessels can become damaged. This can lead to other complications such as kidney failure, eye failure and impotence.
The FDA already knows that the effectiveness of dapagliflozin is reduced when used in treating diabetes in patients who also have kidney problems. There are two different types of diabetes and kidney problems are likely in persons who have had diabetes for a long time without knowing.
Unfortunately, patients who were using dapagliflozin to treat diabetes were found to have unexpected complications resulting from their use of the diabetes treatment drug.
The Eat to Live Plan to Prevent and Reverse Diabetes
Diabetes patients using dapagliflozin were seen to have more breast and bladder cancers. Nine bladder cancers were found in a group of 5,478 diabetes patients who were using dapagliflozin to treat diabetes. In a group of 3,156 diabetes patients who were not using dapagliflozin as a diabetes treatment, only one case of bladder cancer was found.
Among a group of 2,223 women who were using dapagliflozin for treating diabetes, nine cases of breast cancer were found. Among a group of 1,053 women who were not using the drug for diabetes treatment, only one case of breast cancer was found.
Diabetes patients who used dapagliflozin also experienced side effects such as genital infections and urinary tract infections.